MONICA V. MAHONEY, PHARMD, BCPS AQ-ID, BCIDP*

A review of the neutralizing antibody that was studied in a phase 2/3 trial in outpatients with mild to moderate infections of COVID-19.

Contagion® radio is here to bring joy with every new antibiotic alert!

Fosfomycin is an attractive potential option because it does not cross-react with other antimicrobials, making it a good choice in patients with extensive drug allergies.